secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-02-11T23:59:59+00:00
Accession:  0001645113-26-000010
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud

FDA Approves Novocure's Optune Pax for Locally Advanced Pancreatic Cancer
-------------------------------------------------------------------------

- FDA approval based on Phase 3 PANOVA-3 trial in 571 patients with locally advanced pancreatic cancer.
- Median overall survival improved to 16.2 months vs 14.2 months (HR 0.82, p=0.039).
- Time to pain progression extended by 6.1 months (15.2 vs 9.1 months).
- First new treatment approved for locally advanced pancreatic cancer in nearly 30 years.
- Optune Pax well-tolerated; most adverse events were mild-to-moderate skin reactions under arrays.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000010/0001645113-26-000010-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000010/nvcr-20260211.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000010

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer